Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 1/2001

01-07-2001 | Original Article

Combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin for metastatic urothelial cancer

Authors: Iwao Fukui, Junji Yonese, Tetsuro Tsukamoto, Tetsuya Yoshida, Taisei Kim, Tsuguhiro Tohma, Daisuke Ishiwata

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2001

Login to get access
Metadata
Title
Combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin for metastatic urothelial cancer
Authors
Iwao Fukui
Junji Yonese
Tetsuro Tsukamoto
Tetsuya Yoshida
Taisei Kim
Tsuguhiro Tohma
Daisuke Ishiwata
Publication date
01-07-2001
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2001
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800100320

Other articles of this Issue 1/2001

Cancer Chemotherapy and Pharmacology 1/2001 Go to the issue

Original Article

Expression and integrity of DNA topoisomerase II isoforms does not explain generic drug resistance in malignant mesothelioma

Original Article

Fendiline, an anti-anginal drug, increases intracellular Ca2+ in PC3 human prostate cancer cells

Original Article

Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration

Original Article

Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients

Original Article

Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer

Original Article

Plasmid expression of a peptide that selectively blocks oncogenic ras-p21-induced oocyte maturation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits